Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5)
- PMID: 3199066
- PMCID: PMC2189157
- DOI: 10.1084/jem.168.6.2007
Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5)
Abstract
TNF induces hemorrhagic necrosis (HN) when injected into skin exposed to bacterial agents but not when injected into normal skin. In this paper, we present several lines of evidence suggesting that TNF requires the fifth component of complement (C5) to induce HN in skin exposed to bacteria. First, mouse strains that do not have C5 did not develop HN after injection of TNF and bacteria into skin. Second, plasma from C5-sufficient mice could correct the defect in these C5-deficient mice. Third, heating at 56 degrees C for 30 min inactivated the capacity of plasma to reconstitute C5-deficient mice. Fourth, CVF, which is known to inactivate complement, abrogated the capability of C5-sufficient mice to respond. Fifth, depleting plasma of hemolytic activity while generating C5a did not affect the capacity of the activated plasma to reconstitute C5-deficient mice. Finally, only the plasma fraction containing molecules of the size range of C5a reconstituted C5-deficient mice. These findings indicate that C5a and not the membrane attack complex is required for HN. Although we do not know through which mechanism C5a participates in the development of HN, we propose that the described HN response is related to a local defense mechanism in which TNF and C5a lead to the disruption of capillaries in the direct vicinity of bacteria. By this mechanism the rapid spread of bacteria or their products into the circulation is prevented. Such a tissue response is consistent with the known higher susceptibility of C5-deficient mice to bacterial infections and provides a model with which to search for the multiple steps involved in this important local defense mechanism.
Similar articles
-
Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock.Infect Immun. 1993 Apr;61(4):1474-81. doi: 10.1128/iai.61.4.1474-1481.1993. Infect Immun. 1993. PMID: 8454352 Free PMC article.
-
A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration.J Immunol. 2001 Feb 15;166(4):2479-86. doi: 10.4049/jimmunol.166.4.2479. J Immunol. 2001. PMID: 11160308
-
The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin.Immunology. 1990 Jul;70(3):309-14. Immunology. 1990. PMID: 2379939 Free PMC article.
-
Possible involvement of C5/C5a in the efferent and elicitation phases of contact sensitivity.J Immunol. 1996 Jun 15;156(12):4444-50. J Immunol. 1996. PMID: 8648091
-
C5a as a mediator of cutaneous inflammation.Am J Dermatopathol. 1987 Apr;9(2):138-43. doi: 10.1097/00000372-198704000-00009. Am J Dermatopathol. 1987. PMID: 3332749 Review.
Cited by
-
Glucocorticoid-mediated inhibition of endotoxin-induced intratumor tumor necrosis factor production and tumor hemorrhagic necrosis and regression.J Exp Med. 1989 Sep 1;170(3):703-10. doi: 10.1084/jem.170.3.703. J Exp Med. 1989. PMID: 2788707 Free PMC article.
-
Effects of sphingosine and sphingosine analogues on the free radical production by stimulated neutrophils: ESR and chemiluminescence studies.Mediators Inflamm. 1997;6(5-6):327-33. doi: 10.1080/09629359791460. Mediators Inflamm. 1997. PMID: 18472867 Free PMC article.
-
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8955-9. doi: 10.1073/pnas.92.19.8955. Proc Natl Acad Sci U S A. 1995. PMID: 7568051 Free PMC article.
-
Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.J Transl Med. 2018 Aug 31;16(1):242. doi: 10.1186/s12967-018-1611-7. J Transl Med. 2018. PMID: 30170620 Free PMC article. Review.
-
Induction of inflammatory cell infiltration and necrosis in normal mouse skin by the combined treatment of tumor necrosis factor and lithium chloride.Am J Pathol. 1991 Mar;138(3):727-39. Am J Pathol. 1991. PMID: 1848044 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous